呼吸器内科 論文(2019年)
英語論文
1: Kobayashi H, Serizawa M, Naito T, Konno H, Kojima H, Mizuno T, Isaka M, Endo M, Nagashima T, Kusuhara M, Urakami K, Ohshima K, Yamaguchi K, Ohde Y, Takahashi T. Characterization of tumour mutation burden in patients with non-small cell lung cancer and interstitial lung disease. Respirology. 2019 ;25(8):850–4.
2: Wakuda K, Miyawaki T, Miyawaki E, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Nakashima K, Ono A, Kenmotsu H, Naito T, Murakami H, Mori K, Endo M, Takahashi T. Efficacy of Second-line Chemotherapy in Patients With Sensitive Relapsed Small-cell Lung Cancer. In Vivo. 2019 ;33(6):2229-2234.
3: Kawamura T, Naito T, Kobayashi H, Nakashima K, Omori S, Wakuda K, Ono A, Kenmotsu H, Murakami H, Endo M, Takahashi T. Acquired immunodeficiency associated with thymoma: a case report. BMC Cancer. 2019 ;19(1):762.
4: Nakashima K, Kimura M, Akamatsu H, Daga H, Imai H, Taira T, Ko R, Hisamatsu Y, Nishino K, Sugimoto T, Miyashita Y, Takahashi T; et al. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. Jpn J Clin Oncol. 2019 ;49(7):671-675.
5: Ono A, Isaka M, Serizawa M, Omae K, Kojima H, Nakashima K, Omori S, Wakuda K, Kenmotsu H, Naito T, Murakami H, Urakami K, Nagashima T, Sugino T, Kusuhara M, Takahashi T, Yamaguchi K, Ohde Y. Corrigendum to “Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer” [Lung Cancer 128 (2019) 152-157]. Lung Cancer. 2019 ;130:226.
6: Miyawaki E, Kenmotsu H, Mori K, Harada H, Mitsuya K, Mamesaya N, Kawamura T, Kobayashi H, Nakashima K, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Endo M, Nakasu Y, Gon Y, Takahashi T. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases. Int J Radiat Oncol Biol Phys. 2019 ;104(3):604-613.
7: Nakashima K, Akamatsu H, Murakami H, Niwa T, Iwamoto Y, Ozawa Y, Yokoyama T, Shoda H, Yamamoto N, Yoshioka H, Masuda K, Naito T, Mori K, Takahashi T. Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer. Anticancer Res. 2019 ;39(3):1463-1468.
8: Fujio T, Nakashima K, Naito T, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Murakami H, Takahashi T. Platinum Combination Chemotherapy Is Poorly Tolerated in Malnourished Advanced Lung Cancer Patients with Poor Performance Status. Nutr Cancer. 2019 ;71(5):767-771.
9: Ono A, Isaka M, Serizawa M, Omae K, Kojima H, Nakashima K, Omori S, Wakuda K, Kenmotsu H, Naito T, Murakami H, Urakami K, Nagashima T, Sugino T, Kusuhara M, Takahashi T, Yamaguchi K, Ohde Y. Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer. Lung Cancer. 2019 ;128:152-157.
10: Naito T, Mitsunaga S, Miura S, Tatematsu N, Inano T, Mouri T, Tsuji T, Higashiguchi T, Inui A, Okayama T, Yamaguchi T, Morikawa A, Mori N, Takahashi T, Strasser F, Omae K, Mori K, Takayama K. Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer. J Cachexia Sarcopenia Muscle. 2019 ;10(1):73-83.